Company Developments - Illumina, Inc. has received approval from Japan's Ministry of Health, Labour and Welfare for its TruSightTM Oncology (TSO) Comprehensive test, aimed at enhancing precision oncology accessibility [1] - The TSO Comprehensive is the first U.S. FDA-approved comprehensive genomic profiling in vitro diagnostics kit with pan-cancer companion diagnostics claims [5] - The test analyzes DNA and RNA variants across more than 500 genes, aiding in the identification of clinically actionable biomarkers for targeted therapy selection [6] - Illumina's oncology portfolio is set to be showcased at the ASCO Annual Meeting in Chicago from May 30 to June 3 [2] Financial Performance - Following the announcement of the TSO Comprehensive approval, Illumina's stock price increased by 2.6%, closing at $82.49 [3] - The company has a market capitalization of $12.72 billion and an earnings yield of 5.3%, significantly higher than the industry's -31.5% yield [4] - Illumina has achieved an earnings beat of 56.4% on average over the trailing four quarters [4] Industry Prospects - The global precision genomic testing market was valued at $15.49 billion in 2024 and is projected to grow at a compound annual growth rate of 14.8% through 2030 [7] - The rising demand for precision genomic testing is driven by the need for early disease detection and effective treatment planning [7] Other Developments - Illumina launched the DRAGEN version 4.4 software, which includes oncology applications for clinical research and supports new multiomics assays [8][10] - The company is collaborating with Ovation.io, Inc. to develop a large clinical multiomic dataset from 25,000 patients, aimed at advancing drug discovery [10]

veracyte. Q1 2025 Earnings Presentation May 7, 2025 2 © 2025 Veracvte. Inc. All rights reserved. © 2025 Veracyte, Inc. All rights reserved. 3 Forward-looking statements and non-GAAP information This presentation contains forward-kodoling, statements, including, but not lintied to our plans, dbjectives, and expectives, and expectabions (financial and othernise), i 2025 and 2020 fina vial and operating results our assumptions for future reveave royst: plans and friming of the release of version 2.0 cour' leng ...

More than half say genetic testing for mental health medications could reduce concernsSALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, I ...